Charles Schwab Investment Management Inc Nektar Therapeutics Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,454,168 shares of NKTR stock, worth $1.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,454,168
Previous 1,487,730 2.26%
Holding current value
$1.56 Million
Previous $1.84 Million 2.49%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$1.11 - $1.48 $37,253 - $49,671
-33,562 Reduced 2.26%
1,454,168 $1.89 Million
Q2 2024

Aug 12, 2024
BUY
$0.9 - $1.83 $323,469 - $657,722
359,411 Added 31.85%
1,487,730 $1.84 Million
Q1 2024

May 08, 2024
BUY
$0.49 - $0.96 $16,852 - $33,017
34,393 Added 3.14%
1,128,319 $1.05 Million
Q4 2023

Feb 06, 2024
BUY
$0.42 - $0.57 $8,348 - $11,329
19,877 Added 1.85%
1,093,926 $612,000
Q3 2023

Nov 08, 2023
BUY
$0.51 - $1.05 $37,748 - $77,717
74,017 Added 7.4%
1,074,049 $644,000
Q2 2023

Aug 09, 2023
SELL
$0.53 - $1.03 $107,821 - $209,540
-203,437 Reduced 16.9%
1,000,032 $580,000
Q1 2023

May 11, 2023
SELL
$0.64 - $3.15 $110,542 - $544,077
-172,723 Reduced 12.55%
1,203,469 $842,000
Q4 2022

Feb 13, 2023
BUY
$2.03 - $4.28 $34,333 - $72,387
16,913 Added 1.24%
1,376,192 $3.11 Million
Q3 2022

Nov 14, 2022
BUY
$3.04 - $5.14 $150,850 - $255,057
49,622 Added 3.79%
1,359,279 $4.35 Million
Q2 2022

Aug 15, 2022
BUY
$3.17 - $6.17 $1.15 Million - $2.23 Million
361,720 Added 38.16%
1,309,657 $4.98 Million
Q1 2022

May 13, 2022
BUY
$4.16 - $13.72 $71,011 - $234,200
17,070 Added 1.83%
947,937 $5.11 Million
Q4 2021

Feb 11, 2022
BUY
$10.83 - $18.41 $252,274 - $428,842
23,294 Added 2.57%
930,867 $12.6 Million
Q3 2021

Nov 16, 2021
BUY
$13.07 - $18.84 $213,145 - $307,242
16,308 Added 1.83%
907,573 $16.3 Million
Q2 2021

Aug 16, 2021
BUY
$16.52 - $20.4 $327,922 - $404,940
19,850 Added 2.28%
891,265 $15.3 Million
Q1 2021

May 17, 2021
SELL
$16.56 - $25.46 $2.15 Million - $3.31 Million
-129,946 Reduced 12.98%
871,415 $17.4 Million
Q4 2020

Feb 16, 2021
BUY
$15.77 - $19.03 $779,495 - $940,633
49,429 Added 5.19%
1,001,361 $17 Million
Q3 2020

Nov 13, 2020
BUY
$16.59 - $24.79 $387,127 - $578,474
23,335 Added 2.51%
951,932 $15.8 Million
Q2 2020

Aug 14, 2020
BUY
$16.86 - $23.44 $1.55 Million - $2.15 Million
91,885 Added 10.98%
928,597 $21.5 Million
Q1 2020

May 15, 2020
BUY
$14.47 - $27.96 $772,046 - $1.49 Million
53,355 Added 6.81%
836,712 $14.9 Million
Q4 2019

Feb 07, 2020
SELL
$15.87 - $23.12 $4.23 Million - $6.16 Million
-266,568 Reduced 25.39%
783,357 $16.9 Million
Q3 2019

Nov 08, 2019
BUY
$16.91 - $36.27 $5.06 Million - $10.9 Million
299,269 Added 39.87%
1,049,925 $19.1 Million
Q2 2019

Aug 09, 2019
BUY
$31.0 - $36.3 $852,810 - $998,612
27,510 Added 3.8%
750,656 $26.7 Million
Q1 2019

May 14, 2019
BUY
$31.58 - $46.35 $660,053 - $968,761
20,901 Added 2.98%
723,146 $24.3 Million
Q4 2018

Feb 14, 2019
BUY
$30.43 - $56.65 $787,741 - $1.47 Million
25,887 Added 3.83%
702,245 $23.1 Million
Q3 2018

Nov 13, 2018
SELL
$46.46 - $68.49 $9.77 Million - $14.4 Million
-210,336 Reduced 23.72%
676,358 $41.2 Million
Q2 2018

Aug 08, 2018
SELL
$46.25 - $104.45 $12.6 Million - $28.4 Million
-271,546 Reduced 23.44%
886,694 $43.3 Million
Q1 2018

May 07, 2018
BUY
$57.4 - $108.44 $20.4 Million - $38.6 Million
355,766 Added 44.33%
1,158,240 $123 Million
Q4 2017

Jan 17, 2018
BUY
$23.02 - $60.5 $2.28 Million - $6 Million
99,192 Added 14.1%
802,474 $47.9 Million
Q3 2017

Nov 13, 2017
BUY
$17.79 - $24.0 $12.5 Million - $16.9 Million
703,282
703,282 $16.9 Million

Others Institutions Holding NKTR

# of Institutions
147
Shares Held
139M
Call Options Held
32.6K
Put Options Held
14.1K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email